BCAX (Bicara Therapeutics) FCF Yield % : -12.98 (As of Apr. 07, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Bicara Therapeutics's Trailing 12-Month Free Cash Flow is $-74.82 Mil, and Market Cap is $576.31 Mil. Therefore, Bicara Therapeutics's FCF Yield % for today is -12.98%.

The historical rank and industry rank for Bicara Therapeutics's FCF Yield % or its related term are showing as below:

BCAX' s FCF Yield % Range Over the Past 10 Years
Min: -12.98 Med: 0 Max: 0
Current: -12.98

BCAX's FCF Yield % is ranked better than
54.08% of 1496 companies
in the Biotechnology industry
Industry Median: -15.915 vs BCAX: -12.98

Bicara Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Bicara Therapeutics FCF Yield % Historical Data

The historical data trend for Bicara Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics FCF Yield % Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

FCF Yield %

-7.89

Bicara Therapeutics Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Bicara Therapeutics's FCF Yield %

For the Biotechnology subindustry, Bicara Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Bicara Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-74.822	/	948.3448
	=	-7.89%

Bicara Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/	948.3448
	=	0.00%

Bicara Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Bicara Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.